Sevelamer Does Not Decrease Lipopolysaccharide or Soluble CD14 Levels But Decreases Soluble Tissue Factor, Low-Density Lipoprotein (LDL) Cholesterol, and Oxidized LDL Cholesterol Levels in Individuals With Untreated HIV Infection

Abstract

NCT 01543958.

Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART

“…However, we could not demonstrate any significant effect on microbial translocation assessed by plasma LPS or sCD14 analyses. This is in line with most recent studies targeting the intestinal microbiota, including intervention with the probiotic/prebiotic combination given to SIV-infected macaques, 26 the LPS-binding agent Sevelamer, 47 the nonabsorbable antibiotic Rifaximin, 48 and the fungus S. boulardii, 46 showing no reduction in LPS or sCD14 levels.…”

Microbial translocation and microbiome dysbiosis in HIV-associated immune activation

“…Administration of sevelamer did not reduce plasma LPS concentrations in patients in the chronic stage of HIV infection, but did produce potential cardiovascular benefits [107*]. Similarly, treatment of HIV-infected individuals with hyperimmue bovine colostrum containing anti-LPS antibodies did not reduce plasma LPS concentrations [108].…”

Infection par le virus de l’immunodéficience humaine

“…La translocation peut également être diminuée grâce à des substances capables de réduire la charge microbienne dans la lumière digestive comme la rifaximine, un antibiotique à large spectre [2]. D'autres molécules ont la capacité de se fixer, dans la lumière digestive, aux endotoxines bactériennes et de les neutraliser avant leur translocation, comme le lactulose, le carbonate de sévélamer 4 qui régule la phosphorémie [53], ou encore des immunoglobulines isolées de sérum bovin [54]. L'association de ces stratégies thérapeutiques pourrait permettre d'améliorer à la fois la qualité de la réponse antimicrobienne et la capacité de contrôler la réplication virale [29].…”